Diffuse Midline Glioma, H3 K27M-Mutant research hub
5 indexed studies · 5 currently recruiting
- recruitingPHASE1
CAR T Cells to Target GD2 for DMG
This study looks at a new treatment called GD2 CAR T cells for children and young adults aged 2-16 with a type of brain tumour called Diffuse Midline Glioma (DMG). It aims to see if the treatment is safe and how well the body uses it.
United Kingdom - recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
This study looks at how new ways of classifying brain tumours (cIMPACT-NOW and 2021 WHO) help us understand treatment and what to expect. Researchers want to see if these new classifications group patients better and lead to clearer treatment guidelines for different types of brain tumours.
Austria · Belgium · France - recruitingPHASE2
Study of Olutasidenib and Temozolomide in HGG
This study is for young people aged 12-39 with a type of brain tumour called high-grade glioma (HGG) that has a specific IDH1 gene change. It tests if a new drug, olutasidenib, combined with standard treatment, can help patients live longer after radiotherapy.
United States · Australia · Canada - recruitingPHASE2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
This study is looking at new drug combinations to treat certain types of brain tumours in children and young adults. It aims to see if combining ribociclib with either everolimus or temozolomide can help patients live longer and improve their health.
United States · Australia · Canada - recruiting
Targeted Pediatric High-Grade Glioma Therapy
This study aims to understand childhood brain tumours better by looking at their genes. For children, teenagers, and young adults with newly diagnosed high-grade gliomas, including DIPG, doctors will check their tumour's genetic makeup to see if they might be suitable for specific new treatments in future trials.
United States · Australia · Canada